Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06529705
NCT06529705CompletedNot Applicable

Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1)

University Hospital, Montpellier1 site in 1 country21 target enrollmentStarted: August 19, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
21
Locations
1
Primary Endpoint
Change in the percentage of time in range 70-180 mg/dL
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

EkiYou-Study-1 is an interventional before/after clinical investigation according to EU 2017/745. It is conducted in 21 adults with diabetes and treated by multiple daily insulin injections.

After a run-in period of 2 weeks, participants will receive for 6 weeks EkiYou V2 application that will help them to estimate their daily bolus and basal insulin doses. This device weekly adjusts insulin parameters including : basal insulin dose, insulin to carb ratios and correction factor.

The aim of the study is to assess the safety and performance of EkiYou V2 device. Data on glycemic control, safety, quality of life and satisfaction of participants will be collected.

Detailed Description

Participants of the study must be adults treated by multiple daily insulin injection in a basal/bolus insulin schema and users of a continuous glucose monitor (CGM). The study involves 5 visits, each two weeks. Participants will be included for 8 weeks divided in two distinct periods :

  • Run-in period for two weeks to collect glycemic control at baseline with their standard insulin management
  • Intervention period for 6 weeks where participant will receive the investigational device EkiYou V2 to manage their insulin injection.

EkiYou V2 device is a new version of the previously CE-Marked device EkiYou V1. It is a decision support that include the following features to participants:

  • Carbohydrate counting through an extensive food database with more than 200k items.
  • Bolus calculation based on their meal, physical activity and blood glucose.
  • Bolus correction advice.
  • Long-acting insulin reminders and automatic periodic titration.
  • Insulin-to-carb ratios and correction factor automatic adjustment.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Be over 18 years old;
  • •Have type 1, type 2, or pancreatogenic diabetes;
  • •Have been treated with multiple daily injections of insulin in a basal/bolus regimen for at least 6 months;
  • •Be using a continuous glucose monitoring device such as Dexcom G6, Dexcom One or Freestyle Libre for at least 2 weeks;
  • •Have a time in the glycemic target range (70-180 mg/dl) of less than 70%;
  • •Require at least 15 units of insulin therapy per day;
  • •Use a rapid-acting insulin compatible with the device, such as Novorapid, Humalog, Apidra, Asparte, Sanofi, Fiasp, or Lyumjev;
  • •Use a long-acting insulin compatible with the device, such as Lantus, Abasaglar, Toujeo, Levemir, or Tresiba;
  • •Be able to read and use a smartphone;
  • •Have no visual impairment requiring a specific font for smartphones;
  • •Have basic knowledge of smartphone use;
  • •Indicate their willingness to follow the protocol and sign a written informed consent

Exclusion Criteria

  • •Ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within 6 months prior to inclusion;
  • •Treatment with any hypoglycemia-inducing agent other than insulin (including sulfonylureas and SGLT-2 inhibitors);
  • •Daily insulin requirement exceeding 200 U/day;
  • •Suffering from gastroparesis;
  • •Pancreatopathy secondary to chronic alcoholism;
  • •Known medical condition that, in the investigator's opinion, may interfere with the protocol;
  • •Participation in another clinical trial or administration of an unapproved medication within 4 weeks prior to screening;
  • •Not affiliated with a social security system;
  • •Vulnerable subject: minors, or adults under protection as defined by the Public Health Code, pregnant or breastfeeding women, subjects under guardianship or deprived of liberty;
  • •Person under legal protection;
  • •Person participating in another study with an ongoing exclusion period

Arms & Interventions

Adults with diabetes treated by MDI

Experimental

Intervention: EkiYou V2 (Device)

Outcomes

Primary Outcomes

Change in the percentage of time in range 70-180 mg/dL

Time Frame: Through study completion, an average of 8 weeks

Time in range is the amount of time spent in the target glucose range-between 70 and 180 mg/dL-as measured by CGM

Secondary Outcomes

  • Number of non-serious adverse events related or unrelated to the device(Through study completion, an average of 8 weeks)
  • Number of serious clinical adverse events (SAEs)(Through study completion, an average of 8 weeks)
  • Number of other serious adverse events related or unrelated to the device(Through study completion, an average of 8 weeks)
  • Number of non-serious and unexpected adverse events related to the device(Through study completion, an average of 8 weeks)
  • Change in the percentage of time below 54 mg/dL(8 weeks follow-up)
  • Change in the percentage of time below 70 mg/dL(8 weeks follow-up)
  • Change in the percentage of time above 180 mg/dL(8 weeks follow-up)
  • Change in the percentage of time above 250 mg/dL(8 weeks follow-up)
  • Change in the Glucose Management Indicator (GMI)(8 weeks follow-up)
  • Percentage of patients with time in range 70-180 mg/dL above or equal to 70%(8 weeks follow-up)
  • Change in Mean blood glucose level(8 weeks follow-up)
  • Change in Coefficient of variation of blood glucose(8 weeks follow-up)
  • Number of level 2 hypoglycemic episodes(8 weeks follow-up)
  • Total Daily Insulin (Units/kg)(2 weeks follow-up)
  • Change in Total Daily Insulin (Units/kg)(8 weeks follow-up)
  • Total Insulin Delivered Via Basal (Units/kg)(2 weeks follow-up)
  • Change in total Insulin Delivered Via Basal (Units/kg)(8 weeks follow-up)
  • Number per day and total Insulin Delivered Via Bolus (Units/kg)(2 weeks follow-up)
  • Change in number per day and total Insulin Delivered Via Bolus (Units/kg)(8 weeks follow-up)
  • Number of connectivity issues with the application reported by the user(8 weeks follow-up)
  • Questionnaire System Usability scale(8 weeks follow-up)
  • Diabetes Treatment Satisfaction Questionnaire (DTSQ)(8 weeks follow-up)
  • Hypoglycemia Fear Survey 2 (HFS II)(8 weeks follow-up)
  • Number of daily insulin injections calculated from application data(8 weeks follow-up)
  • Average number of daily interactions calculated from application data(8 weeks follow-up)
  • Number of active application users(8 weeks follow-up)
  • Change in the percentage of time below 54 mg/dL(2 weeks follow-up)
  • Change in the percentage of time below 70 mg/dL(2 weeks follow-up)
  • Change in the percentage of time above 180 mg/dL(2 weeks follow-up)
  • Change in the percentage of time above 250 mg/dL(2 weeks follow-up)
  • Change in the Glucose Management Indicator (GMI)(2 weeks follow-up)
  • Percentage of patients with time in range 70-180 mg/dL above or equal to 70%(2 weeks follow-up)
  • Change in Mean blood glucose level(2 weeks follow-up)
  • Change in Coefficient of variation of blood glucose(2 weeks follow-up)
  • Number of level 2 hypoglycemic episodes(2 weeks follow-up)
  • Diabetes Treatment Satisfaction Questionnaire (DTSQ)(At inclusion visit)
  • Hypoglycemia Fear Survey 2 (HFS II)(At inclusion visit)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsAdvanced Solid Tumor
NCT03903705Hutchmed348
Terminated
Phase 1
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced CancersSolid Tumor
NCT03139370Kite, A Gilead Company16
Active, not recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)HemoglobinopathiesSickle Cell Disease
NCT04853576Editas Medicine, Inc.45
Active, not recruiting
Not Applicable
Estudio para evaluar la eficacia y seguridad del tratamiento del estudio como primera linea de tratamiento en pacientes con cáncer gástrico Her 2 positivoCáncer GástricoMedDRA version: 14.0Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-001231-23-ESFundación para el Progreso de la Oncología en Cantabria
Recruiting
Phase 2
Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myelomarelapsed and/or refractory multiple myeloma
JPRN-UMIN000003076ara Hospital Kinki University School Of Medicine20